1. Litigation Support
1.1      Capabilities
1.2      Risks in Perspective
1.3      Plaintiff Viewer
1.4      Test Plaintiff Selection
           1.4.1    Advantages of Random Test Plaintiff Selection
1.5      Example Activities
1.6      Litigation History

2. Regulatory Risk Assessment
2.1      Risk Assessments Developed Under Regulatory Guidelines
2.2      Risks from Naturally Occurring Carcinogens and Human Activities
2.3      Example Activities
2.4      Brief Overview of Recent Regulatory History in the USA
           2.4.1    Summary
           2.4.2    Timeline for Establishment of Agencies
           2.4.3    Statutory Timeline
           2.4.4    Supplemental Regulations
           2.4.5    Highlights for Some Agencies
           2.4.6    History of the California Environmental Protection Agency
           2.4.7    History of Food Regulation

3. Human Health Risk Assessment
3.1      Quantitative Risk Assessment and Statistical Analysis
3.2      Importance of Dose and Dose-Response Relationships
3.3      Misuse of Regulatory Upper-Bound Risk Characterizations
3.4      Risk Characterization Choices and Risk Exaggeration
3.5      A Better Approach to Cancer Risk Characterization
3.6      Overview of Background, Motivation, and Statistical Methods for Margin-of-Exposure Characterizations of Cancer Risks
           3.6.1    Importance of Dose
           3.6.2    Dose-Response Modeling
           3.6.3    Dose-Response Models
           3.6.4    Maximum Likelihood Estimation
           3.6.5    Multistage Model
           3.6.6    Example of Fitted Multistage Model
           3.6.7    Potency
           3.6.8    Linearized Multistage Model
           3.6.9    Overstatement of Risks by the Linearized Multistage Model
           3.6.10  Adverse Impacts of the Variability in the Magnitude of the Bias in the Linearized Multistage Model's Overstatement of Risks
           3.6.11  Non-Responsiveness of the Linearized Multistage Model to Data
           3.6.12  Ranking Relative Risks
           3.6.13  Added Risk versus Extra Risk
           3.6.14  Need for a Better Dose-Response Characterization
           3.6.15  Better Dose-Response Characterization
           3.6.16  Benchmark Doses
           3.6.17  Responsiveness of Benchmark Doses Data Versus the Relative Non-Responsiveness of the Regulatory Upper-Bound Potency Q1* based on the Linearized Multistage Model
           3.6.18  Recommended Dose-Response Characterization
           3.6.19  Margin-of-Exposure Characterizations
           3.6.20  Conclusion
           3.6.21  Figures 1 to 16
3.7      Innovative Risk Assessment
3.8      Components of High-to-Low-Dose Extrapolation and Dose-Response Modeling
3.9      Probabilistic Exposure Assessment
3.10    Aggregate Risk Assessment
3.11    Cumulative Risk Assessment
3.12    Example Activities

4. Statistics
4.1      General Statistical Expertise
4.2      Monte Carlo Simulation Techniques
4.3      Scientific Notation

5. Software
5.1      Dose-Response Modeling Tools
5.2      Exposure Assessment Tools
5.3      Risk Characterization Tools
5.4      Statistical Tools
5.5      Operations Research and Mathematical Programming Algorithms
5.6      Predecessor Website